MorphoSys to Receive Milestone Payment for Guselkumab Phase 3 Program
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys to Receive Milestone Payment for Guselkumab Phase 3 Program
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced
today that its collaborator Janssen Biotech, Inc. has initiated a phase 3
clinical trial in moderate to severe plaque-type psoriasis with the HuCAL
antibody guselkumab (CNTO1959). The event triggered a clinical milestone payment
to MorphoSys. Further financial details were not disclosed.
"Our therapeutic antibody pipeline represents the main value driver for
MorphoSys and we are delighted to see our third HuCAL antibody advancing into
late-stage clinical development. With every phase 3 start, the time when the
first HuCAL antibody drug could enter the market gets closer" commented Dr.
Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
MorphoSys's clinical pipeline currently comprises 21 antibodies. Of these, 18
are programs that were initiated by partners, of which three are in phase 3
development, eight are in phase 2 and seven are in phase 1. From the company's
proprietary portfolio, MOR202, which is being co-developed with Celgene, is in a
phase 1/2a trial for multiple myeloma. MOR208 is currently being evaluated in
phase 2 trials in B-ALL, NHL and CLL. The third proprietary compound, MOR103,
partnered with GSK, has concluded a phase 1b/2a trial in rheumatoid arthritis
and a phase 1b trial in multiple sclerosis.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 80 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Specialist Corporate Communications & IR
Jessica Rush
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1865038/654743.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#1865038]
Unternehmensinformation / Kurzprofil:
Datum: 22.10.2014 - 23:57 Uhr
Sprache: Deutsch
News-ID 346303
Anzahl Zeichen: 4851
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Receive Milestone Payment for Guselkumab Phase 3 Program"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
